Daniel Harrison, MD
Advanced Heart Failure and Transplant Cardiology · Kansas City, KSNPI 1104357631
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,067 of the $1,304 with a category attached, or 81.8%. 16 manufacturers reported payments, led by Abbott at 35.8% of the total. 2025 is the largest year on record at $801, 2.6 times the $304 reported in 2023.
Across 44 payments — averaging $29.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$467
- E.r. Squibb & Sons, L.L.C.$107
- Merck$106
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$103
- Endotronix, Inc.$100
- AstraZeneca$88
- plus $333 from 10 others
What the payments were for
- Food & beverage$1,06782%
- Education$23718%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 7 | $467 |
| E.r. Squibb & Sons, L.L.C. | 6 | $107 |
| Merck | 6 | $106 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $103 |
| Endotronix, Inc. | 1 | $100 |
| AstraZeneca | 5 | $88 |
| Edwards Lifesciences | 2 | $60 |
| Impulse Dynamics (USA) Inc. | 2 | $58 |
| Novo Nordisk | 3 | $58 |
| Amgen | 2 | $36 |
| Pfizer | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Atricure, Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Ancora Heart, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few advanced heart failure and transplant cardiology providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Furosemide | 12 | $62 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Kansas City
- Zubair ShahKansas City$387K
- Hirak ShahKansas City$29K
- Pradeep MammenKansas City$18K
- Tarun DaliaKansas City$16K
- Michelle DimzaKansas City$12K
- Raja ZaghlolKansas City$5K
- Mohamed El KhashabKansas City$4K
- Jane TitteringtonKansas City$4K
- Paola RoldanKansas City$3K
- Deepthi VodnalaOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.